RFM
APLS

Royal Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History

Royal Fund Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-400
Closed -$10K – 168
2020
Q1 		$10K Buy
+400
New +$14.2K ﹤0.01% 366

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Royal Fund Management's APLS Position: Q2 2020 in Review

Royal Fund Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2020, closing a stake of 400 shares — an estimated $10K sold.

Royal Fund Management first reported a position in APLS in Q1 2020 and held it in 1 quarter. The position peaked at $10K in Q1 2020. 142 funds tracked by Wall St. Rank hold APLS as of Q2 2020.

  • Royal Fund Management reported no remaining Apellis Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Royal Fund Management sold 400 Apellis Pharmaceuticals shares in Q2 2020, an estimated $10K.
  • Royal Fund Management first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Royal Fund Management's Apellis Pharmaceuticals position peaked at $10K in Q1 2020.
  • 142 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.